Equities

Cann Group Ltd

Cann Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.05
  • Today's Change0.002 / 4.17%
  • Shares traded585.47k
  • 1 Year change-68.50%
  • Beta1.5611
Data delayed at least 20 minutes, as of Jun 07 2024 06:57 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cann Group Limited is an Australia-based company that is focused on developing, producing, and supplying innovative cannabis medicines. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the group, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. It operates through cultivation of the medicinal cannabis segment. The Company supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. It also owns Satipharm and its patent-protected capsule technology. The Company's research, cultivation, and good manufacturing practices (GMP) manufacturing facilities are in Melbourne, and a cultivation and GMP manufacturing facility is near Mildura, Victoria.

  • Revenue in AUD (TTM)16.45m
  • Net income in AUD-29.28m
  • Incorporated2015
  • Employees40.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Patrys Ltd1.70m-5.12m16.46m15.00--3.28--9.71-0.0025-0.00250.00080.00240.1978--0.5828---59.77-43.96-68.99-47.06-----302.26-230.44----0.00---14.4540.52-4.15------
BTC Health Ltd16.03k-8.26m16.53m1.00--3.0510.011,031.21-0.0305-0.03050.000050.01670.0017--0.031---89.67-23.15-91.36-24.64-----51,522.02-2,498.18---0.07870.00---86.04-26.76-1,665.01------
Oncosil Medical Ltd355.30k-11.71m16.66m2.00--2.56--46.89-0.0081-0.00810.00020.0020.0506--7.88---166.55-57.65-234.81-64.83-426.96---3,295.08-473.02---68.930.0256---59.92-37.72-5.74--40.13--
Auscann Group Holdings Ltd2.05m-9.44m17.61m27.00------8.60-0.0213-0.02170.00430.01620.1674--5.35---77.15-39.85-78.72-40.73100.59---460.74-925.91---23.160.00--13.8851.3757.10------
Rhythm Biosciences Ltd157.67k-8.63m17.65m----12.90--111.95-0.0386-0.03860.00070.00550.0263--1.81---144.00-106.11-169.71-125.51-1,899.74-1,210.71-5,473.20-6,642.262.04--0.0304--814.1828.776.55---20.43--
Lumos Diagnostics Holdings Ltd12.28m-13.19m17.81m----1.29--1.45-0.0354-0.03540.03490.02870.34182.246.37---36.70-40.15-55.14-56.6759.7345.97-107.38-162.900.479-6.250.4803---9.4239.2980.38---38.50--
Algorae Pharmaceuticals Ltd84.10k-2.25m18.56m----5.12--220.71-0.0015-0.00150.000060.00220.0245--1.79---65.51-46.12-70.91-53.52-----2,678.04-591.05---136.750.00--1,132.26-44.06-7.68------
LBT Innovations Limited2.00m-21.38m18.77m17.00--6.91--9.37-0.0428-0.04280.00380.0020.10870.08192.25117,882.40-115.89-28.85-131.86-30.9994.76---1,066.62-441.763.30-6.850.5633---5.29-18.45-239.17---34.63--
Amplia Therapeutics Ltd1.87m-4.46m20.10m1.00--1.00--10.76-0.0224-0.02240.00940.07390.0949--0.7018---22.64-25.27-26.24-26.78-----238.69-342.26----0.1318---42.1012.31-71.30--31.88--
Immuron Ltd3.58m-3.88m20.52m6.00--1.17--5.74-0.017-0.0170.01570.07690.16640.64687.92596,106.70-18.06-27.48-19.86-29.5880.8777.52-108.52-296.647.79-2.850.0023--135.85-13.34-32.66--3.27--
Cann Group Ltd16.45m-29.28m21.87m40.00--0.4306--1.33-0.0724-0.07240.04060.11610.12370.39527.37---22.03-22.28-34.23-24.4321.11---178.07-407.570.0861-5.880.5646--114.9089.76-27.66---11.16--
Acrux Ltd14.46m-709.00k22.68m43.00--4.01--1.57-0.0024-0.00240.05020.01951.29--4.86---6.34-39.91-9.21-46.0072.38---4.90-132.53----0.2861--133.7428.2992.23---16.66--
BPH Energy Ltd345.67k894.65k22.95m2.00k20.410.9868--66.400.0010.0010.00040.02030.0177--5.97--4.58-6.894.78-7.7256.39--258.50-357.76----0.0043--96.545.21179.13------
Noxopharm Ltd3.90m-12.13m23.38m1.00k--3.56--5.99-0.0415-0.04150.01340.02250.2684--1.643,901.84-83.43-50.96-94.78-62.98-----310.82-191.70---1.470.00--11.3244.0219.34------
Tryptamine Therapeutics Ltd1.21m-4.32m25.05m----3.72--20.75-0.0162-0.01620.00370.00620.2368-------84.69-66.34-120.26-79.70-----357.70-228.11---21.620.00---18.97138.7329.29--68.45--
Alterity Therapeutics Ltd123.46k-12.28m26.23m11.00--0.7951--212.42-0.005-0.0050.000050.00630.0044--1.5211,223.64-44.20-53.02-53.57-61.96-----9,947.97-40,995.62----0.0143--557.60-39.40-7.47---34.88--
Data as of Jun 07 2024. Currency figures normalised to Cann Group Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
DFA Australia Ltd.as of 30 Apr 2024453.82k0.00%
Data from 30 Apr 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.